The clinical impact of Nintedanib and Pirfenidone on pulmonary circulation of interstitial pneumonia: A Hyogo-IP multicenter prospective observational study - The clinical impact of Nintedanib and Pirfenidone on pulmonary circulation of interstitial pneumonia: A Hyogo-IP multicenter prospective observational study

Start Date07 Apr 2021

Sponsor / Collaborator

Shinko Hospital

JPRN-UMIN000031173

/ CompletedNot ApplicableIIT

Combined effect of progressive resistance training and physical activity counseling in patients with chronic obstructive pulmonary disease: a randomized controlled crossover study. - Combined effect of progressive resistance training and physical activity counseling in patients with COPD

Start Date01 Apr 2017

Sponsor / Collaborator

Shinko Hospital

JPRN-UMIN000025162

/ CompletedNot ApplicableIIT

Effect of electrical muscle stimulation-induced passive leg cycle ergometer training on ventilated intensive care unit patients. - Effect of hybrid EMS on ventilated ICU patients.

Start Date01 Oct 2016

Sponsor / Collaborator

Shinko Hospital

100 Clinical Results associated with Shinko Hospital

0 Patents (Medical) associated with Shinko Hospital

398

Literatures (Medical) associated with Shinko Hospital

24 Mar 2025·Cureus

Translaminar Screw Fixation for Giant C1 Lateral Mass Metastasis From Hepatocellular Carcinoma

Article

Author: Sakisuka, Ryo ; Sugita, Yoshito ; Hayashi, Hideki ; Toda, Hiroki ; Hashikata, Hirokuni

Metastatic spinal tumors at the craniovertebral junction (CVJ) are exceedingly rare, with limited reports of C1 lateral mass metastases from hepatocellular carcinoma (HCC). This report presents a case in which posterior fixation alone successfully achieved pain relief and improved stability in a patient with HCC metastasis involving extensive osteolysis of a C1 lateral mass and encasement of the vertebral artery. A 71-year-old male presented with a worsening right cervical pain. The patient had been prescribed nonsteroidal anti-inflammatory drugs and opioid analgesics, yet the pain remained unresolved. Computed tomography (CT) revealed a 5.5 cm osteolytic tumor at the C1 lateral mass with circumferential involvement of the vertebral artery. The patient was diagnosed with spinal metastasis from HCC, characterized by spinal instability (Spinal Instability Neoplastic Score (SINS), 11) and intractable pain (visual analog scale (VAS), 7.7). The patient was bedridden because of an inability to support head loads (performance status (PS), 4), and it was considered difficult to initiate ongoing chemotherapy. The patient was referred for surgical intervention to relieve the pain and improve stability. To address the pain and instability, occipitocervical (C2-C5) posterior fixation was performed without tumor resection. Due to extensive tumor invasion, pedicle screw placement at C2 was not feasible, and C2 translaminar screw fixation was selected instead. Postoperatively, the patient experienced significant pain relief and regained ambulatory ability. At one month postoperatively, fixation remained stable, with VAS improving to 0.8 and PS to 1. The patient was able to maintain pain relief and exhibited improved stability, allowing him to walk, and durvalumab/tremelimumab chemotherapy was initiated two months after surgery. The primary goals of managing metastatic tumors at the CVJ are pain relief, neurological function preservation, and spinal stability. In this case, posterior fixation alone achieved substantial pain alleviation and stability improvement without tumor resection. Notably, the use of C2 translaminar screws minimized the risks of spinal cord and vertebral artery injuries while ensuring effective stabilization. This is the first report to demonstrate the efficacy of posterior fixation alone for HCC metastases with complete destruction of the articular facet at C1. Posterior fixation alone can provide effective pain relief and restore stability in metastatic tumors with severe osteolysis of the C1 lateral mass. Careful selection of fixation techniques can minimize intraoperative complications while improving the patient's quality of life. This report contributes to surgical strategies for similar cases.

01 Mar 2025·Cytotherapy

Comparison of methotrexate dosing protocols for graft-versus-host disease prophylaxis after unrelated hematopoietic stem cell transplantation

Article

Author: Watanabe, Mitsumasa ; Nakamura, Naokazu ; Imada, Kazunori ; Akasaka, Takashi ; Kanda, Junya ; Mitsuyuki, Satoshi ; Takaya, Ryosuke ; Tsunemine, Hiroko ; Takeoka, Tomoharu ; Takaori-Kondo, Akifumi ; Hishizawa, Masakatsu ; Yonezawa, Akihito ; Kubo, Tomoyo ; Itoh, Mitsuru ; Kondo, Tadakazu ; Oka, Satoko ; Yago, Kazuhiro ; Kitano, Toshiyuki ; Ikeda, Takashi

BACKGROUND AIMSMethotrexate (MTX) is used as standard graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation. However, the optimal dosing regimen among the various MTX regimens available remains unclear.METHODSWe used the registration data of Kyoto Stem Cell Transplantation Group to compare six MTX dosing protocols in a multicenter retrospective analysis of 816 cases of unrelated bone marrow or peripheral blood stem cell transplantation.RESULTSOur findings indicated increased risks of grade Ⅱ-Ⅳ acute GVHD and extensive chronic GVHD in the cohort given the shortened mini-dose MTX regimen (5 mg/m² infusions on days 1, 3, and 6) compared with patients that received any of the other protocols. In addition, transplantation outcomes did not differ significantly between cohorts according to the inclusion or absence of leucovorin rescue.CONCLUSIONThe original short-term, reduced short-term, and mini-dose MTX methods were all effective for GVHD prophylaxis. However, omission of the day 11 MTX dose from the mini-dose regimen elevated the risks of grade Ⅱ-Ⅳ acute GVHD and extensive chronic GVHD. Moreover, leucovorin rescue might be ineffective in terms of reducing complications.

01 Mar 2025·Internal Medicine

Pathogenic <i>TNFRSF13B</i> Variant in an Adult Japanese Patient with Common Variable Immunodeficiency

Article

Author: Nakamura, Naokazu ; Ikunari, Ryo ; Arima, Nobuyoshi ; Tanaka, Yasuhiro ; Takeda, June ; Tsunemine, Hiroko

Common variable immunodeficiency (CVID) is a primary B cell immunodeficiency disorder. Symptoms do not develop immediately after birth, and patients are often diagnosed in childhood and adulthood. These patients often develop autoimmune diseases and malignant tumors. We herein report a 50-year-old woman with severe hypogammaglobulinemia and recurrent respiratory tract infections who was diagnosed with CVID. Target sequencing showed a TNFRSF13B heterozygous frameshift variant. The patient had many comorbidities, probably caused by a CVID-induced immune imbalance. Physicians who treat adult patients are often unaware of CVID. CVID should be recognized as a differential diagnosis in hypogammaglobulinemia and recurrent infections.

100 Deals associated with Shinko Hospital

100 Translational Medicine associated with Shinko Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Shinko Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 12 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing